IMMUNIZATION COVID-19 UPDATE

ISSUE NO 1 | FEBRUARY 5, 2021

QUESTION OF THE WEEK:

How do I get my second dose? The pharmacy tells me they don't have any more appointments?

The Office of Public Health has advised all vaccine providers that they will automatically receive enough second doses to vaccinate those who were administered a first dose. It is the responsibility of the provider to alert every person who receives an initial dose as to the day, time and location for getting the second dose of the vaccine. Providers have been directed to schedule people for their second doses before the person exits the vaccination site and/or provide the person with an appointment reminder card or a secure electronic reminder notice.

WEEKLY COVID-19 VACCINE UPDATE

Here is an overview of major updates that occurred over the week.

Johnson & Johnson COVID-19 Vaccine

Johnson & Johnson announced on January 29, 2021, that the topline efficacy and safety data from the Phase 3 ensemble clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies, met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The vaccine candidate was overall 66% effective in preventing moderate to severe COVID-19 infection. It is estimated the J&J vaccine will be ready for distribution mid-March. The J&J vaccine will also be administered as a single dose, meaning it will not require the 2-dose series like Moderna and Pfizer. VACCINE DOSES ADMINISTERED IN LOUISIANA

534,985

J & J COVID-19 VACCINE

Johnson & Johnson announce single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its Phase 3 trial.

VACCINE ELIGIBILITY GROUPS HAVE EXPANDED

New people and providers are eligible for the vaccine under Phase 1B, Tier 1.

Federal Retail Pharmacy Program for COVID-19 Vaccination

The federal government has partnered with 21 national pharmacy chains and independent pharmacy networks to help administer COVID-19 vaccine in communities across the United States as part of the Federal Retail Pharmacy Program for COVID-19 Vaccination.

The program will be implemented incrementally, based on the available supply of COVID-19 vaccines. As part of this initial phase, select retail pharmacies in each state and U.S. territory will receive a limited supply of COVID-19 vaccine directly from the federal government to vaccinate eligible individuals in their communities.

This phase of the program is designed to engage the system in a limited way to ensure the infrastructure is ready for large scale implementation when vaccine supply increases. Eventually, as vaccine supply increases, more than 40,000 pharmacy locations nationwide will be providing COVID-19 vaccine through the program.

The CDC has developed a <u>webpage</u> that provides the name of pharmacy partners currently participating in the program by state (<u>https://www.cdc.gov/vaccines/covid-19/retail-pharmacy-program/participating-pharmacies.html</u>).

Eligibility Groups Have Expanded

Louisiana is expanding the criteria for individuals eligible to receive a COVID-19 vaccine. This change is effective Monday, February 8, 2021. Louisiana providers who are administering the COVID-19 vaccine must adhere to the guidance developed by the Louisiana Department of Health to ensure an equitable approach to making vaccinations available to as many people as possible in the eligible groups.

The following are the people and providers who are newly eligible for the vaccine under Phase 1, Tier 1:

- Persons ages 65 and older
- Louisiana Unified Command Group and essential COVID response personnel (requires prior designation by state authorities)
- Police and other first responders



COVID-19 Vaccine Demographics

SERIES INITIATED BY RACE:

- White: 46.35%
- Black: 15.85%
- American Indian: 0.17%
- Asian: 1.49%
- Native Hawaiian: 0.16%
- Unknown: 15.29%
- **Other:** 20.69%

SERIES INITIATED BY AGE:

- **5-17:** 0.02%
- 18-29: 5.04%
- **30-39:** 7.71%
- **40-49:** 8.42%
- 50-59: 10.13%
- 60-69: 12.6%
- **70+:** 56.09%

SERIES INITIATED BY GENDER:

- Female: 60.43%
- Male: 39.19%
- Unknown: 0.38%

Race data completeness is expected to improve as we continue our outreach with vaccine providers.

ADDITIONAL RESOURCES

Moderna Trainings

- Wednesday, February 10, 2021 | 3 p.m. ET

 <u>https://tinyurl.com/moderna07</u>
- Wednesday, February 17, 2021 | 1 p.m. ET
 - <u>https://tinyurl.com/moderna08</u>

COVID-19 Information for Healthcare Providers LDH webpage

• https://ldh.la.gov/index.cfm/page/3880

Pfizer-BioNTech COVID-19 Vaccine Website

https://www.cvdvaccine-us.com/

Moderna COVID-19 Vaccine Website

<u>https://www.modernatx.com/covid19vaccine-eua/</u>